柳叶刀肿瘤学:每年与肥胖相关的癌症高达50万例
2014/11/27
11月26日《柳叶刀肿瘤学》“The Lancet Oncology”杂志发表了一项研究报告:由IARC(国际癌症研究中心)的科学家组成的研究小组在2012年对全球184个国家的因癌症死亡人群做的统计分析中的数据表明:全球青少年每年因肥胖和超重带来大约50万的新增癌症,且正以3.6%的增长率上涨。


11月26日《柳叶刀肿瘤学》“The Lancet Oncology”杂志发表了一项研究报告:由IARC(国际癌症研究中心)的科学家组成的研究小组在2012年对全球184个国家的因癌症死亡人群做的统计分析中的数据表明:全球青少年每年因肥胖和超重带来大约50万的新增癌症,正以3.6%的增长率上涨。研究者还表示四分之一的因肥胖导致的癌症案例是可以避免的。


研究中的超重及肥胖均以BMI指数(即身体质量指数,称简体质指数又称体重,英文为Body Mass Index,简称BMI),是用体重公斤数除以身高米数平方得出的数字,是目前国际上常用的衡量人体胖瘦程度以及是否健康的一个标准。当BMI为25-29.9时即被认为是超重,当BMI指数超过30时,既定为肥胖。


统计数据表明:在男性中,有13.6万因肥胖的癌症,超过了大肠癌和肾癌的三分之二;在女性中,有34.5万与肥胖相关的癌症,接近乳腺癌、子宫肌瘤和大肠癌总和的三分之一。

癌症高发区域在发达国家蔓延最快,北美为最高,占三分之一。撒哈拉以南的非洲地区因与肥胖相关的癌症最少,仅有7300例。

领衔这项研究的Melina Arnold表示:我们的研究也进一步证实了全球的肥胖人群越来越多。现阶段的肥胖人群是上世纪80年代的2倍,从而加剧了全球的癌症负担,特别是在南美州和北非,是近30年来肥胖增长最高的地区。

延伸阅读:

Overweight linked to 500,000 cancer cases per year

Fat to blame for half a million cancers a year, WHO agency says

Study: Being overweight or obese led to 481,000 cancers in one year

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
  • 2019/01/30
    Neurocrine Biosciences和Voyager Therapeutics公司联合宣布达成战略合作,共同开发和推广Voyager公司的基因疗法项目。
  • 2018/11/23
    日前,瑞士公司Santhera Pharmaceuticals和Idorsia宣布达成合作协议。Santhera将从Idorsia获取用于治疗杜氏肌营养不良症(DMD)的2期临床在研药物vamorolone的全球研发许可(除日本和韩国以外)。Vamorolone是一种“first-in-class”创新类固醇药物,它有潜力成为治疗DMD年轻患者的标准类固醇疗法。
  • 2018/11/19
    动脉网获悉,美国东部时间2018年11月15日,Mission Therapeutics与AbbVie签署合作协议,旨在开发用于治疗阿尔茨海默病和帕金森病的靶向去泛素化酶(DUBs)药物。
查看更多
  • Global burden of cancer attributable to high body-mass index in 2012: a population-based study

    Background:High body-mass index (BMI; defined as 25 kg/m2 or greater) is associated with increased risk of cancer. To inform public health policy and future research, we estimated the global burden of cancer attributable to high BMI in 2012. Methods:In this population-based study, we derived population attributable fractions (PAFs) using relative risks and BMI estimates in adults by age, sex, and country. Assuming a 10-year lag-period between high BMI and cancer occurrence, we calculated PAFs using BMI estimates from 2002 and used GLOBOCAN2012 data to estimate numbers of new cancer cases attributable to high BMI. We also calculated the proportion of cancers that were potentially avoidable had populations maintained their mean BMIs recorded in 1982. We did secondary analyses to test the model and to estimate the effects of hormone replacement therapy (HRT) use and smoking. Findings:Worldwide, we estimate that 481 000 or 3·6% of all new cancer cases in adults (aged 30 years and older after the 10-year lag period) in 2012 were attributable to high BMI. PAFs were greater in women than in men (5·4% vs 1·9%). The burden of attributable cases was higher in countries with very high and high human development indices (HDIs; PAF 5·3% and 4·8%, respectively) than in those with moderate (1·6%) and low HDIs (1·0%). Corpus uteri, postmenopausal breast, and colon cancers accounted for 63·6% of cancers attributable to high BMI. A quarter (about 118 000) of the cancer cases related to high BMI in 2012 could be attributed to the increase in BMI since 1982. Interpretation:These findings emphasise the need for a global effort to abate the increasing numbers of people with high BMI. Assuming that the association between high BMI and cancer is causal, the continuation of current patterns of population weight gain will lead to continuing increases in the future burden of cancer. Funding:World Cancer Research Fund International, European Commission (Marie Curie Intra-European Fellowship), Australian National Health and Medical Research Council, and US National Institutes of Health.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test